These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 27069028

  • 1. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
    Dowling AK, Liptrot SD, O'Brien D, Vandenberghe E.
    Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
    [Abstract] [Full Text] [Related]

  • 2. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
    Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.
    Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
    [Abstract] [Full Text] [Related]

  • 3. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
    Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, Lin K, Pettitt AR, Kneba M, Montserrat E, Cymbalista F, Hallek M, Hillmen P, Ghia P, European Research Initiative in CLL.
    Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
    [Abstract] [Full Text] [Related]

  • 4. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML, Almeida J, Vidriales B, López-Berges MC, García-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A.
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [Abstract] [Full Text] [Related]

  • 5. Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.
    Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, Béné MC.
    Cytometry B Clin Cytom; 2011 Nov; 80(6):346-53. PubMed ID: 21976156
    [Abstract] [Full Text] [Related]

  • 6. A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia.
    Sartor MM, Gottlieb DJ.
    Cytometry B Clin Cytom; 2013 Mar; 84(2):96-103. PubMed ID: 23283845
    [Abstract] [Full Text] [Related]

  • 7. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
    Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P.
    Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
    [Abstract] [Full Text] [Related]

  • 8. 14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL.
    Goshaw JM, Gao Q, Wardrope J, Dogan A, Roshal M.
    Cytometry B Clin Cytom; 2021 Jul; 100(4):509-518. PubMed ID: 32896973
    [Abstract] [Full Text] [Related]

  • 9. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
    Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F.
    Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
    [Abstract] [Full Text] [Related]

  • 10. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
    Chen X, Chen X, Zhao S, Shi Y, Zhang N, Guo Z, Qiao C, Jin H, Zhu L, Zhu H, Li J, Wu Y.
    Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
    [Abstract] [Full Text] [Related]

  • 11. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
    Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M.
    Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
    [Abstract] [Full Text] [Related]

  • 12. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.
    Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P.
    Blood; 2001 Jul 01; 98(1):29-35. PubMed ID: 11418459
    [Abstract] [Full Text] [Related]

  • 13. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR, Wang H, Chang Y, Cheng YF, Fu JY, Zhang LP, Liu GL, Chen SS.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun 01; 26(6):327-31. PubMed ID: 16185473
    [Abstract] [Full Text] [Related]

  • 14. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
    Böttcher S, Ritgen M, Pott C, Brüggemann M, Raff T, Stilgenbauer S, Döhner H, Dreger P, Kneba M.
    Leukemia; 2004 Oct 01; 18(10):1637-45. PubMed ID: 15343348
    [Abstract] [Full Text] [Related]

  • 15. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S, Della Starza I, De Propris MS, Del Giudice I, Mauro FR, Marinelli M, Di Maio V, Piciocchi A, Foà R, Guarini A.
    Br J Haematol; 2014 Aug 01; 166(3):360-8. PubMed ID: 24735016
    [Abstract] [Full Text] [Related]

  • 16. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Bazinet A, Rys RN, Barry A, Greenwood CMT, Young YK, Mendoza A, LaPorta I, Wever CM, Mercier FE, Johnson NA.
    Leuk Lymphoma; 2021 Oct 01; 62(10):2352-2359. PubMed ID: 34020575
    [Abstract] [Full Text] [Related]

  • 17. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M, Schinkoethe T, Elter T.
    Cancer Invest; 2005 Oct 01; 23(6):488-96. PubMed ID: 16203656
    [Abstract] [Full Text] [Related]

  • 18. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.
    Bento L, Correia R, de Sousa F, Vaz A, Pedro E, Schimidell D, Millan N, Passaro M, Barroso R, Bacal N.
    Cytometry B Clin Cytom; 2020 Nov 01; 98(6):529-535. PubMed ID: 32251553
    [Abstract] [Full Text] [Related]

  • 19. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.
    Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M.
    Leukemia; 2009 Nov 01; 23(11):2007-17. PubMed ID: 19641522
    [Abstract] [Full Text] [Related]

  • 20. Flow cytometric analysis of CD5+ B cells: a frame of reference for minimal residual disease analysis in chronic lymphocytic leukemia.
    Gupta R, Jain P, Deo SV, Sharma A.
    Am J Clin Pathol; 2004 Mar 01; 121(3):368-72. PubMed ID: 15023041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.